Ventyx Biosciences Share Holder Equity 2021-2024 | VTYX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Ventyx Biosciences share holder equity from 2021 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Ventyx Biosciences share holder equity from 2021 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$171.5B
Vertex Pharmaceuticals (VRTX)	$121.6B
Gilead Sciences (GILD)	$111.4B
Bristol Myers Squibb (BMY)	$110.2B
Regeneron Pharmaceuticals (REGN)	$93B
CSL (CSLLY)	$90B
GSK (GSK)	$76.4B
Argenex SE (ARGX)	$35.6B
Alnylam Pharmaceuticals (ALNY)	$35.3B
BioNTech SE (BNTX)	$26.5B
Biogen (BIIB)	$25.3B
Illumina (ILMN)	$23.9B
Moderna (MRNA)	$21B
BeiGene (BGNE)	$19.9B
Genmab (GMAB)	$14.9B
Incyte (INCY)	$14.7B
Exact Sciences (EXAS)	$12.9B
BioMarin Pharmaceutical (BMRN)	$12.7B
Vaxcyte (PCVX)	$12B
Bio-Techne Corp (TECH)	$11.9B
Sarepta Therapeutics (SRPT)	$11.8B
Insmed (INSM)	$11.7B
QIAGEN (QGEN)	$9.8B
Exelixis (EXEL)	$9.7B
Bio-Rad Laboratories (BIO.B)	$9.3B
Revolution Medicines (RVMD)	$9.2B
Intra-Cellular Therapies (ITCI)	$9.2B
Roivant Sciences (ROIV)	$8.6B
Viking Therapeutics (VKTX)	$8.1B
Legend Biotech (LEGN)	$8.1B